In Germany, the sales of medicinal cannabis was at a steady increase until it boomed in the second quarter of 2019. By comparison to the second quarter of 2018, 74% more medical cannabis was reimbursed by German insurers this year. In May, it had surpassed the 10 million euro mark ever since this framework was implemented in 2017, however it dropped to 9.5 million euro in June.
The types of medicinal cannabis that were sold
This data which is published by the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) includes all medical cannabis sold until June 2019. These categories include cannabis preparations such as dronabinol, ground flower and full spectrum extracts, finished pharmaceutical products such as Sativex and Canemes, and unprocessed cannabis flower. The unprocessed flowers and flowers used in preparations represent 55% of the total reimbursed cannabis products during the second quarter. However, more flower was sold using private prescriptions which wasn’t applied to the data. Nevertheless, reimbursement among all categories of products grew.